Medicine
Hympavzi 150 mg/1 mL injection
Hympavzi 150 mg/1 mL injection is a prescription medicine containing Marstacimab for subcutaneous use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Once stored at room temperature, do not return to the refrigerator and discard…
Key facts
- Active ingredient (INN)
- Marstacimab
- Brand
- Hympavzi
- Strength
- 150 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1 mL
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Once stored at room temperature, do not return to the refrigerator and discard after 7 days. • Do not freeze. • Do not shake. Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. • If needed, HYMPAVZI may be stored one time at room temperature [up to 86°F (30°C)] in its original carton to protect from light for up to 7 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B02BX11 Marstacimab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 November 2024
- Identifiers
- RxCUI 2697139, 2697146, 2697150 +5DailyMed set ID a2cc631e-13a6-40c2-acf9-065ccedfb90aNDC 0069-2151, 0069-1510Application BLA761369
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / 1 mL in 1 syringe | 0069-1510-01 | Pfizer Laboratories | 15 October 2025 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 0069-2151-01 | Pfizer Laboratories | 5 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Marstacimab
Clinical summary
Marstacimab is a prescription medicine indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Marstacimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MarstacimabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- HYMPAVZI prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Hympavzi: European public assessment report (EPAR) · European Medicines Agency
Need Hympavzi 150 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.